Jounce Therapeutics is dedicated to transforming the treatment of cancer.Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce’s technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.
Recent Press Releases
12/07/17Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference...
View More Releases
NASDAQ GS JNCE (Common Stock)
$21.72 - 1.38 (5.97%)
Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.
02/23/18 4:00 p.m. ET
View More Events